Effect of Immune-enhancing Enteral Nutrition on Immunomodulation in Critically Ill Patients
Effects of Enteral Formula Including Immune-modulating Nutrients on Clinical Course and Immune Function in Critically Ill Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ICU patients
Exclusion Criteria:
- ICU patients who could not receiving enteral nutrition
Study Plan
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: control group
standard enteral nutrition
|
standard enteral nutrition
Other Names:
|
|
Experimental: test group I
high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan
|
high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan
Other Names:
|
|
Experimental: test group II
high-protein enteral nutrition of immune modulating nutrients without β-glucan
|
high-protein enteral nutrition of immune modulating nutrients without β-glucan
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline NK cell activity at 7 days
Time Frame: at baseline and 7 days follow-up
|
NK cell activity (%)
|
at baseline and 7 days follow-up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline IL-12 at 7 days
Time Frame: at baseline and 7 days follow-up
|
IL-12 (pg/mL)
|
at baseline and 7 days follow-up
|
|
Change from baseline hs-CRP at 7 days
Time Frame: at baseline and 7 days follow-up
|
hs-CRP (mg/dL)
|
at baseline and 7 days follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jong Ho Lee, Ph. D., Dept. of Food and Nutrition, College of Human Ecology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-749, South Korea
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BT_ICU_immune
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.